Bayer’s first-quarter results update shows that its workforce has declined by more than 1,500 full-time equivalent (FTE) employees since the end of last year, suggesting r
A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA, shortly after it showed preliminary signs of efficac
Bayer has joined forces with Google Cloud to continue development of an artificial intelligence-powered platform to help radiologists diagnose patients quicker and more ef
Bayer chief executive Bill Anderson has followed through on a pledge to streamline the group’s management, starting at the very top with a big reduction in the pharma unit
Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a chall
Bayer chief executive Bill Anderson pulled no punches in his assessment of the company at its annual results update, saying it is “badly broken” by patent losses, litigati